Genetic markers associated with dihydroartemisinin–piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype–phenotype association study

The Lancet Infectious Diseases

Volumn 17, Issue 2, 2017, Pages 164-173

  Amato, Roberto ^a,b   Lim, Pharath ^c,d   Miotto, Olivo ^a,b,e   Amaratunga, Chanaki ^c   Dek, Dalin ^d   Pearson, Richard D ^a,b   Almagro Garcia, Jacob ^a,b   Neal, Aaron T ^c   Sreng, Sokunthea ^d   Suon, Seila ^d   Drury, Eleanor ^a   Jyothi, Dushyanth ^a   Stalker, Jim ^a   Kwiatkowski, Dominic P ^a,b   Fairhurst, Rick M ^c  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d National Center for Parasitology Entomology and Malaria Control   (Cambodia)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; DIHYDROARTEMISININ PLUS PIPERAQUINE; EXONUCLEASE; HEMOGLOBIN; HEMOZOIN; MOLECULAR MARKER; MULTIDRUG RESISTANCE PROTEIN 1; PIPERAQUINE; PLASMEPSIN II; PLASMEPSIN III; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; GENETIC MARKER; QUINOLINE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CAMBODIA; CHROMOSOME 13; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; EXON; GENE AMPLIFICATION; GENETIC MARKER; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IC50; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PARASITE ISOLATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL ANALYSIS; SURVIVAL RATE; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; GENETIC ASSOCIATION STUDY; GENETICS; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; TREATMENT FAILURE;

ANTIMALARIALS; ARTEMISININS; CAMBODIA; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INHIBITORY CONCENTRATION 50; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINOLINES; TREATMENT FAILURE;

EID: 85006176728     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30409-1     Document Type: Article

References (27)

1. 1 WHO. Guidelines for the treatment of malaria, 3rd edition, 2015, World Health Organization Press, Geneva.
2. 2 Fairhurst, RM, Understanding artemisinin-resistant malaria: what a difference a year makes. Curr Opin Infect Dis 28 (2015), 417–425.
3. 3 Amaratunga, C, Sreng, S, Suon, S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 12 (2012), 851–858.
4. 4 Amaratunga, C, Lim, P, Suon, S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 16 (2016), 357–365.
5. 5 Dondorp, AM, Nosten, F, Yi, P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361 (2009), 455–467.
6. 6 Ariey, F, Witkowski, B, Amaratunga, C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505 (2014), 50–55.
7. 7 Ashley, EA, Dhorda, M, Fairhurst, RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371 (2014), 411–423.
8. 8 Takala-Harrison, S, Jacob, CG, Arze, C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in southeast Asia. J Infect Dis 211 (2015), 670–679.
9. 9 Leang, R, Barrette, A, Bouth, DM, et al. Efficacy of dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 57 (2013), 818–826.
10. 10 Saunders, DL, Vanachayangkul, P, Lon, C, et al. Dihydroartemisinin–piperaquine failure in Cambodia. N Engl J Med 371 (2014), 484–485.
11. 11 Spring, MD, Lin, JT, Manning, JE, et al. Dihydroartemisinin–piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 15 (2015), 683–691.
12. 12 Leang, R, Taylor, WR, Bouth, DM, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother 59 (2015), 4719–4726.
13. 13 Tun, KM, Imwong, M, Lwin, KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 15 (2015), 415–421.
14. 14 Dondorp, AM, Fairhurst, RM, Slutsker, L, et al. The threat of artemisinin-resistant malaria. N Engl J Med 365 (2011), 1073–1075.
15. 15 Chaorattanakawee, S, Saunders, DL, Sea, D, et al. Ex vivo drug susceptibility testing and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother 59 (2015), 4631–4643.
16. 16 Eastman, RT, Dharia, NV, Winzeler, EA, Fidock, DA, Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother 55 (2011), 3908–3916.
17. 17 Miotto, O, Amato, R, Ashley, EA, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet 47 (2015), 226–234.
18. 18 Snounou, G, Beck, HP, The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 14 (1998), 462–467.
19. 19 Lippert, C, Listgarten, J, Liu, Y, Kadie, CM, Davidson, RI, Heckerman, D, FaST linear mixed models for genome-wide association studies. Nat Methods 8 (2011), 833–835.
20. 20 Purcell, S, Neale, B, Todd-Brown, K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81 (2007), 559–575.
21. 21 WorldWide Antimalarial Resistance Network (WWARN) DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med, 10, 2013, e1001564 discussion e1001564.
22. 22 Miles, A, Iqbal, Z, Vauterin, P, et al. Indels, structural variation, and recombination drive genomic diversity in Plasmodium falciparum. Genome Res 26 (2016), 1288–1299.
23. 23 Pearson, RD, Amato, R, Auburn, S, et al. Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nat Genet 48 (2016), 959–964.
24. 24 Price, RN, Uhlemann, AC, Brockman, A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364 (2004), 438–447.
25. 25 Chugh, M, Sundararaman, V, Kumar, S, et al. Protein complex directs hemoglobin-to-hemozoin formation in Plasmodium falciparum. Proc Natl Acad Sci USA 110 (2013), 5392–5397.
26. 26 Duru, V, Khim, N, Leang, R, et al. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Med, 13, 2015, 305.
27. 27 Miotto, O, Almagro-Garcia, J, Manske, M, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet 45 (2013), 648–655.